High adherence to angiotensin-converting enzyme inhibitor in children and adolescents with Alport syndrome: objective verification using liquid chromatography-mass spectrometry.

Pediatr Nephrol · 2026 · PMC12953493 · PMID 41272348

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Ramipril, an ACEi, was investigated in the randomized placebo-controlled EARLY PRO-TECT Alport trial ( NCT01485978 ) and showed a trend towards slowed disease progression with early treatment, without safety concerns compared to placebo [ 21 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.